Day: November 18, 2026

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

-- ELEVATE-45-201 Cohort 2 (10 mg/kg) enrollment complete with data expected in H1 2027 -- BOSTON, Nov. 18, 2026 (GLOBE...

Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026

Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management...

Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium

Orally bioavailable KAT6A degraders demonstrated potent antiproliferative activity in diverse in vivo models of ER+/HER2- breast cancerKAT6A degradation was active...

Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight

Press release – No. 25 / 2026 Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered...

Novo Nordisk Foundation commits US$60 million to strengthen CARB-X efforts against antimicrobial resistance

Four-year renewed commitment will help advance the development of much-needed products to prevent, diagnose, and treat dangerous bacterial infectionsHELLERUP, Denmark...

Portsmouth Square, Inc. Reports First Quarter Fiscal 2027 Results; Pedestrian Bridge Removal Complete and Hotel Reopened After City-Mandated Closure

Los Angeles, California, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Portsmouth Square, Inc. (the “Company” or “Portsmouth”) announced financial results for...

InspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD’s CGuard Prime Carotid Stent Platform

Participating KOLs include six leading physician experts representing vascular surgery, interventional cardiology, vascular medicine, and neurosurgery Webinar to take place...

Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686

IAPRD late-breaking poster shows MDS-UPDRS motor scores remained stable compared to baseline recorded at study entry with no disease progression...

CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics

- CytomX to receive $5 million preclinical milestone payment - - The CytomX and Regeneron collaboration began in 2022 and...

error: Content is protected !!